Dr. Parikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St.
Massachusetts General Hospital
Boston, MA 02114Phone+1 617-726-2862Fax+1 617-724-7441
Summary
- Dr. Aparna Parikh is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Indiana University School of Medicine and completed residency at the MGH and fellowship at UCSF. She specializes in gastrointestinal cancer and has an interest in developmental therapeutics ad liquid biopsies. She also has a background and interest in global health.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2012 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2009 - 2012
Indiana University School of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2012 - Present
MA State Medical License 2016 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Start of enrollment: 2017 Oct 31
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer Start of enrollment: 2020 Apr 16
- A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali Start of enrollment: 2018 Jan 01
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsReverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer.Mihir Rajurkar, Aparna R Parikh, Alexander Solovyov, Eunae You, Anupriya S Kulkarni
Cancer Discovery. 2022-06-02 - 11 citationsDefining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.Ashley M Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu
Nature Reviews. Cancer. 2024-07-01 - 834 citationsColon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi Jen Chen
Journal of the National Comprehensive Cancer Network. 2021-03-02
Journal Articles
- Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic CancerHarvey J Mamon, Paul L Nguyen, Theodore S Hong, Aparna Parikh, Jennifer Y Wo, Rinaa S Punglia, Cristina Ferrone, Ryan D Nipp, Annals of Surgical Oncology
Lectures
- Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastr...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023- Investigating the Use of Circulating Tumor DNA in Early-Stage Colon CancerOctober 7th, 2022
- New Cancer Screen, Same Issues: Can New Test Be Trusted?September 15th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
